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Introduction: Majority of cardiac patients are treated as outpatient. Many studies have documented suboptimal treatment for cardiac patients in 
outpatients especially for minority and low-income population resulting in poor health care outcomes.
Objectives: 1) To Adapt the ACC Guidelines Applied in Practice (GAP) tools to implement real-time decision support during outpatient visits in a 
Federally Qualified Healthcare Center (FQHC). 2) To assess Office-GAP feasibility and impact on both short and long-term medication use.
Method: The process evaluation tested feasibility of using real-time decision support during office-visits. 2 physicians, 1 nurse-practitioner, 8 staff, 
and 95 patients with a diagnosis of CHD or diabetes in one FQHC participated in this pilot study from Sep 2009 to Oct 2011. Patients completed an 
initial visit and 2 follow up GAP visits at 3 and 6 months. Use of GAP tool was assessed at each visit. McNemar’s test was used to examine change 
over time in the proportion of patients using Aspirin/Plavix, ACEi /ARBs, beta-blockers and statins.
Results: Ninety five patients attended the initial visit; 80/95 (84.2%), and 61/80 (76.3%) patients completed first and second GAP visits 
respectively. Mean age was 51.8 + 9.8 years. 52 % males and 49% Whites, BMI was 36.67 + 11.23 and 79% had Diabetes. The Office-GAP tool was 
used 98.7% of the time. We found a significant increase in Aspirin/Plavix use (55% vs. 79%; p=.001), beta-blockers (46% vs. 62 %; p=0.035) and 
weak trends towards increased use of ACEi/ARBs (68% vs. 79%; p=.1) and statins (60% vs. 68% p=.23) between initial visit and 2nd GAP visit. One 
year follow up revealed significant increase of Aspirin/Plavix use (50% vs. 70%; p=0.004) and weak trends towards increased use of ACEi/ARBs (58% 
vs. 63%; p=0.45), beta-blockers (43% vs. 52%; p= 0.18) and statins (62% vs. 67 %; p= 0.45) when compared to Pre-GAP visit.
Conclusions: It is feasible to implement real-time decision support in FQHCs. It facilitated increase compliance with guidelines and medication 
use for minority and low-income populations. Increased medication use continued at 1 year follow up. Further evaluation is needed to establish its 
reach, effectiveness, and cost-effectiveness.
